Increasing Trends of Pharmaceutical Payments to Breast Cancer Specialists in Japan: A Retrospective Study from 2016 to 2019

Abstract

Abstract Introduction: The interplay between pharmaceutical companies and healthcare professionals is a critical facet of modern medicine, with financial relationships often influencing clinical practice. This study examines its impact on clinical practice in Japan, particularly in breast cancer treatment. It aims to uncover the prevalence, magnitude, and trends of payments made to breast cancer specialists by the pharmaceutical industry, thereby increasing transparency in these financial interactions. Methods: A retrospective analysis included breast cancer specialists certified by the Japanese Breast Cancer Society as of May 2023. Payment data from 2016 to 2019 were collected from 93 pharmaceutical companies in the Japan Pharmaceutical Manufacturers Association, focusing on payments for lecturing, writing, and consulting. Results: The analysis revealed an upward trend in pharmaceutical payments, with a total of USD 13,329,910.57 between 2016 and 2019, reflecting an average annual growth rate of 10.1%. The majority of these payments (81.4%) were for speaking engagements. The top 10 pharmaceutical companies made 89.5% of the total payments, with a spike in payments following the introduction of new drugs. Payment distribution was highly concentrated, as evidenced by a high Gini index, indicating a skew towards a few specialists. Conclusion: From 2016 to 2019, there was a notable rise in pharmaceutical payments to Japanese breast cancer specialists, paralleling the introduction of new drugs. The study highlights the need for continuous monitoring of these financial relationships to ensure unbiased clinical decisions and uphold healthcare integrity. Transparent and fair financial practices are essential for maintaining trust in healthcare and prioritizing patient care.